Replies to post #157204 on Anavex Life Sciences Corp (AVXL)

[Doc328]

This is positive for Anavex. Having a speaker presentation will reach more people. It doesn't matter whether they are before or after Biogen. Generally, the clinical study talks and late breaking talks are well attended at subspecialty conferences. I recall a late breaking session at AAN when several MS medications were reporting details of their phase 2 and 3's and there were > 500 in attendance. Nothing wring with sharing the stage. There will be more press and financial types than if they were the only one presenting.